FDA approves Allergan's once-daily eye drop as first-line treatment of elevated intraocular pressure

By Lisa Kerner

Charlotte, N.C., June 23 - Allergan, Inc. said the Food and Drug Administration approved its once-daily prescription eye drop Lumigan (bimatoprost ophthalmic solution) 0.03% as a first-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension.

Lumigan is already established use as a second-line treatment.

Elevated IOP is a risk factor for glaucoma, optic nerve damage and vision loss, according to a company news release.

Lumigan has been reported to increase pigmentation of the iris (likely to be permanent), eyelid and eyelashes, and increase eyelash growth.

About 15% to 45% of patients using Lumigan reported adverse events such as conjunctival hyperemia, growth of eyelashes and ocular pruritus.

Allergan, based in Irvine, Calif., develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention and other specialty markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.